AbbVie shreds alpha-synuclein Parkinson's pact on cusp of phase 2, thinning field led by Roche Arcturus' stock sinks after self-amplifying COVID-19 mRNA vaccine posts 55% efficacy in phase 3 Satellite Bio lifts off with $110M to fuel development of its implantable tissue therapies Sponsored: CDx Biomarkers for Oncology Research & Development Windtree's phase 2 shock med rapidly raises blood pressure—and share price BioXcel will use $260M finance deal to expand indications for schizophrenia drug Tessera Therapeutics stacks up more than $300M in series C funds to bolster new gene-editing platforms As safety signals mount, FDA aims to crack down on PI3K blood cancer nods Philips piles on another trio of Class I recalls for beleaguered ventilator portfolio Groups launch health equity coalition dedicated to chronic disease advocacy Abbott's COVID test sales reach all-time high—and probably for the last time, the company says AbbVie joins roster of Big Pharmas donating Russian profits as war in Ukraine rages on Digital twin generator Unlearn nets $50M to bolster clinical trials with AI models Featured Story | By Nick Paul Taylor AbbVie is bowing out of the alpha-synuclein race. Having taken a drug candidate to the cusp of phase 2, AbbVie has terminated its collaboration with BioArctic, leaving a clutch of rivals such as Novartis and Roche to compete over the Parkinson’s disease opportunity. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor How good does a COVID-19 vaccine need to be to muscle in on the market at this late stage of the game? That is the question facing Arcturus as, armed with evidence of 55% efficacy as a primary series, it gears up for booster trials of its self-amplifying COVID-19 mRNA vaccine in the West. read more By Max Bayer Satellite Bio is lifting off with $110 million in new funds, exiting stealth mode after two years to slingshot its implantable tissue therapy into the clinic. CEO Dave Lennon expects this haul to last at least two years as the company expands its platform and prepares one asset for a phase 1 trial. read more Sponsored by: Precision for Medicine Biomarker discovery and development are critical for advancing oncology therapeutics and informing patient management. Experts discuss evaluating biomarkers in drug-diagnostic co-development programs. read more By Annalee Armstrong Windtree Therapeutics’ cardiogenic shock medicine istaroxime rapidly raised systolic blood pressure in patients with the life-threatening condition, meeting the main goal of a phase 2 study and sending the small biotech’s shares climbing 35% as the markets opened Wednesday. read more By Gabrielle Masson The commercial-stage biopharmaceutical entered a $260 million long-term financing agreement with Oaktree Capital Management and Qatar Investment Authority to accelerate growth and commercially launch a new drug, in return for a share of the profits of any approved therapies. read more By Max Bayer Tessera Therapeutics, concocted by life sciences VC staple Flagship Pioneering, topped more than $300 million in its series C round. The haul brings the company's total amount raised to more than $500 million over 15 months—a plethora of capital to grow out every facet of its business as it pushes toward the clinic. read more By Angus Liu After noticing concerning patient survival data across multiple clinical trials, the FDA is losing confidence in the safety profile of the notoriously toxic PI3K inhibitor drug class for blood cancers. Now, the agency aims to put the meds under a more stringent regulatory scope. read more By Andrea Park There seems to be no limit to Philips’ ventilator safety woes. Nearly a full year after initiating a recall of 5.2 million respiratory devices, the company continues to accumulate safety notices for those and other devices in its vast respiratory portfolio. read more By Anastassia Gliadkovskaya A major purpose of the effort is to avoid duplicating efforts and ensuring all groups’ perspectives and priorities are heard. Its first year, it will focus on obesity. read more By Conor Hale Diagnostic sales last quarter reached a new high point going back all the way to the start of the pandemic, bringing in more than $3.3 billion worldwide. read more By Fraiser Kansteiner This week, AbbVie joined the growing roster of drugmakers that have pledged to donate all Russian profits to Ukrainian relief efforts. The move follows similar vows from Merck & Co., Pfizer, Eli Lilly and GlaxoSmithKline—and it coincides with a renewed philanthropic promise from Swiss pharma Novartis, too. read more By Conor Hale The goal is to help drugmakers and academic researchers complete clinical trials while requiring fewer overall participants. read more Resources Sponsored By: H1 More than 570 clinical trials in Ukraine have been disrupted. Unanticipated disruptions to medical testing and clinical trials impede progress toward new breakthroughs and new therapies that millions of patients around the world hang their hope on. What role do rescue sites play? Sponsored by: Nethealth Net Health, experts in wound care and dermatology clinical trials, have a new eBook: 5 Rules to Enhance Clinical Trials in 2022, find out how to recruit the right participants, connect patients and researchers with technology, manage costs and more. Sponsored by: United Cargo The United Cargo team has made a commitment to pharmaceutical and medical partners that we are equipped to support their vaccine transportation needs safely and effectively across our expansive global and domestic network. The safety and security of these commodities is our priority, and we are proud to be a trusted partner in these efforts. Download infographic now. Presented By: Springer Nature The journey of drug development in 2021 delivered to your inbox: top 10 AdisInsight drug profiles viewed, new drug profiles released, overview of drug launches, key deals, research trends in 2021 and much more (free of charge). Sponsored by: Blue Matter, strategic consultants in the life sciences What’s in store for the oncology market in 2022 and beyond? This paper looks at 5 trends driving the market. Sponsored by: Thermo Fisher Scientific Learn how to position quality as a central component within your raw material sourcing strategies for the chemicals used throughout your workflows. Download the free whitepaper from Thermo Fisher Scientific. Cancer Progress 2022: Hear from Leading Oncology Innovators May 10-12, 2022 | Virtual Accelerating Immuno-Oncology and Oncology Drug Development Using Humanized Mice Live & Recorded on: Thursday, April 21, 2022 | 12pm ET / 9am PT Fierce Trial Master File Summit May 2-4, 2022 | New Orleans, LA & Streaming Live Fierce Leaders in Life Sciences Forum May 24, 2022 | Free Virtual Event Fierce Digital Pharma Engage June 14-15, 2022 | Huntington Beach, CA Fierce Digital Pharma Innovation Week June 21-23, 2022 | Virtual Event Fierce Biotech Next Gen June 29-30, 2022 | Free Virtual Event Fierce Pharma PR & Communications Summit East July 19-20, 2022 | Jersey City, NJ Medical Affairs Strategic Summit West (MASS West) September 20-22, 2022 | San Diego, CA Fierce New Product Planning Summit September 20-22, 2022 | Boston, MA Fierce Digital Pharma East October 18-20, 2022 | Philadelphia, PA & October 25-28, 2022 | Virtual Event Fierce Biotech Cell & Gene Therapy Forum October 19, 2022 | Virtual Event Fierce Pharma Meeting Professionals Summit November 2-3, 2022 | Atlantic City, NJ Fierce European Trial Master File Summit November 14-16, 2022 | London, UK Fierce Launch Readiness for Medical Affairs & Communications Teams Summit November 30-December 1, 2022 | Virtual Event Fierce JPM Week 2023 January 2023 | San Francisco, CA & Virtual | 